Top 10 Companies in the China 2‑Bromopyridine Market (2026): Market Leaders Powering Global Chemical Innovation

MARKET INSIGHTS

The China 2‑Bromopyridine market size was valued at USD 23.5 million in 2024. The market is projected to grow from USD 25.2 million in 2025 to USD 37.8 million by 2034, exhibiting a CAGR of 5.9% during the forecast period.

2‑Bromopyridine is a brominated heterocyclic compound primarily used as a key intermediate in pharmaceutical synthesis and agrochemical production. This versatile chemical building block enables efficient bromination reactions in organic synthesis, particularly for manufacturing active pharmaceutical ingredients (APIs) and specialty chemicals. Recent advancements have expanded its applications in material science, particularly in the development of organic semiconductors and conductive polymers.

The market growth is driven by China’s expanding pharmaceutical sector, which accounted for 58% of domestic consumption in 2024. Rising R&D investments in novel drug formulations have increased demand for high‑purity grades (≥99%), representing 42% of total production volume last year. Furthermore, the compound’s role in synthesizing ligands for catalytic systems has grown by 15% annually since 2022, reflecting broader industrial adoption. Major manufacturers are scaling up production capacity by an average of 8% annually to meet both domestic and export demand, particularly from North American and European markets.

China 2‑Bromopyridine Market – View in Detailed Research Report

Top 10 Companies in the China 2‑Bromopyridine Market (2026)

🔟 10. Zhejiang Kaili Industrial Co., Ltd.

Headquarters: Zhejiang, China
Key Offering: High‑purity 2‑Bromopyridine for pharmaceutical intermediates and specialty chemicals

Zhejiang Kaili Industrial has steadily expanded its production capacity, focusing on advanced purification technologies to meet the stringent requirements of API manufacturers. The company’s investment in continuous‑flow bromination reactors has improved yield and reduced by‑product formation.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling systems
• Adoption of greener bromination catalysts
• Partnerships with academic institutions for process optimization

🟥 9. Nanjing Chemical Material Corp.

Headquarters: Nanjing, China
Key Offering: Bulk 2‑Bromopyridine for agrochemical and organic synthesis applications

Nanjing Chemical Material has leveraged its extensive raw‑material supply chain to offer competitive pricing while maintaining high product quality. The firm is expanding its export footprint to North America and Europe.

Sustainability & Growth Initiatives:

• Investment in low‑energy consumption bromination processes
• Compliance with EU REACH environmental standards
• Development of biodegradable process waste handling

🟠 8. Changzhou Extraordinary Pharmatech Co., Ltd.

Headquarters: Changzhou, China
Key Offering: Specialty 2‑Bromopyridine derivatives for advanced material science and catalytic systems

Changzhou Extraordinary Pharmatech focuses on high‑value derivative synthesis, catering to niche markets such as OLED materials and metal‑free catalytic processes. The company’s R&D pipeline includes novel ligand development for next‑generation catalysts.

Sustainability & Growth Initiatives:

• Implementation of renewable energy sources in production facilities
• Development of zero‑waste production protocols
• Strategic alliances with technology incubators

🟣 7. Changzhou Sunlight Pharmaceutical Co., Ltd.

Headquarters: Changzhou, China
Key Offering: Pharmaceutical‑grade 2‑Bromopyridine for API synthesis

Changzhou Sunlight has adopted continuous‑flow reactors and advanced purification to achieve 99.5%+ purity, meeting the demands of high‑precision API manufacturers. The company’s GMP‑compliant facilities serve both domestic and international clients.

Sustainability & Growth Initiatives:

• Adoption of green bromination catalysts
• Carbon footprint reduction targets
• Participation in industry sustainability forums

🟡 6. Ningbo Inno Pharmachem Co., Ltd.

Headquarters: Ningbo, China
Key Offering: High‑purity 2‑Bromopyridine for pharmaceutical intermediates and specialty chemicals

Ningbo Inno Pharmachem has invested heavily in process automation and quality control, achieving consistent 99%+ purity grades. The firm is expanding its R&D capabilities to develop eco‑friendly bromination processes.

Sustainability & Growth Initiatives:

• Implementation of AI‑driven process optimization
• Reduced energy consumption in bromination reactors
• Collaboration with universities on green chemistry

🟤 5. J&H Chemical Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Bulk 2‑Bromopyridine for agrochemical and organic synthesis applications

J&H Chemical focuses on high‑volume production and has recently upgraded its facilities to incorporate continuous‑flow bromination, improving yield and reducing waste.

Sustainability & Growth Initiatives:

• Adoption of low‑toxicity bromination catalysts
• Investment in waste‑to‑energy conversion
• Expansion of export market into Southeast Asia

🟪 4. Suzhou Health Chemicals Co., Ltd.

Headquarters: Suzhou, China
Key Offering: Pharmaceutical‑grade 2‑Bromopyridine for API synthesis and specialty chemicals

Suzhou Health Chemicals has positioned itself as a key supplier to domestic pharmaceutical manufacturers, focusing on 99%+ purity and GMP compliance.

Sustainability & Growth Initiatives:

• Implementation of closed‑loop water recycling
• Use of renewable energy in production
• Strategic partnerships with pharma R&D labs

🟢 3. Haihang Industry Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Bulk 2‑Bromopyridine for agrochemical and organic synthesis markets

Haihang Industry leverages vertical integration, controlling key raw‑material supplies to maintain competitive pricing while ensuring consistent product quality.

Sustainability & Growth Initiatives:

• Investment in green bromination catalysts
• Adoption of energy‑efficient manufacturing processes
• Expansion into emerging markets in Africa and the Middle East

🟠 2. Shanghai Synica Co., Ltd.

Headquarters: Shanghai, China
Key Offering: Pharmaceutical‑grade 2‑Bromopyridine for API synthesis and specialty chemicals

Shanghai Synica has emerged as a market leader, reporting a 12% year‑over‑year increase in production capacity in 2023. The company’s advanced bromination technologies and GMP‑compliant facilities position it to serve both domestic and international markets.

Sustainability & Growth Initiatives:

• Implementation of green bromination processes
• Investment in continuous‑flow reactors
• Partnerships with biotech firms for antibody‑drug conjugate development

🔵 1. Haihang Industry Co., Ltd.

Headquarters: Shanghai, China
Key Offering: High‑purity 2‑Bromopyridine for pharmaceutical intermediates and specialty chemicals

Haihang Industry has become a leading supplier in the pharmaceutical sector, focusing on high‑purity grades and GMP compliance. The company’s recent investment in continuous‑flow bromination has improved yield and reduced environmental impact.

Sustainability & Growth Initiatives:

• Adoption of renewable energy sources
• Implementation of closed‑loop water systems
• Collaboration with academic institutions on green chemistry research

Download FREE Sample Report

Get Full Report

Outlook: The Future of China 2‑Bromopyridine Market

The China 2‑Bromopyridine market is projected to continue robust growth, driven by expanding pharmaceutical API production, agrochemical innovation, and emerging material science applications. The market is expected to reach USD 38.9 million by 2034, with a steady CAGR of 5.9% over the forecast period.

Future Trends Shaping the Market

• Growth of antibody‑drug conjugate development leveraging 2‑Bromopyridine derivatives
• Expansion of green bromination technologies reducing environmental impact
• Increasing demand for ultra‑high purity grades (≥99.5%) in advanced pharmaceutical and material applications
• Adoption of continuous‑flow reactors and AI‑driven process optimization
• Strategic partnerships between chemical manufacturers and biotech firms for next‑generation drug delivery systems